JP7737219B2 - 潰瘍性大腸炎を治療するための方法 - Google Patents

潰瘍性大腸炎を治療するための方法

Info

Publication number
JP7737219B2
JP7737219B2 JP2019505410A JP2019505410A JP7737219B2 JP 7737219 B2 JP7737219 B2 JP 7737219B2 JP 2019505410 A JP2019505410 A JP 2019505410A JP 2019505410 A JP2019505410 A JP 2019505410A JP 7737219 B2 JP7737219 B2 JP 7737219B2
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
weeks
treatment
clostridium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019505410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019525944A5 (enExample
JP2019525944A (ja
Inventor
トーマス・ジュリアス・ボロディ
Original Assignee
フィンチ セラピューティクス ホールディングス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フィンチ セラピューティクス ホールディングス エルエルシー filed Critical フィンチ セラピューティクス ホールディングス エルエルシー
Publication of JP2019525944A publication Critical patent/JP2019525944A/ja
Publication of JP2019525944A5 publication Critical patent/JP2019525944A5/ja
Priority to JP2022186548A priority Critical patent/JP2023010890A/ja
Application granted granted Critical
Publication of JP7737219B2 publication Critical patent/JP7737219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019505410A 2016-08-03 2017-08-02 潰瘍性大腸炎を治療するための方法 Active JP7737219B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022186548A JP2023010890A (ja) 2016-08-03 2022-11-22 潰瘍性大腸炎を治療するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662370508P 2016-08-03 2016-08-03
US62/370,508 2016-08-03
US15/360,703 2016-11-23
US15/360,703 US20180036352A1 (en) 2016-08-03 2016-11-23 Methods for treating ulcerative colitis
PCT/US2017/045092 WO2018026913A1 (en) 2016-08-03 2017-08-02 Methods for treating ulcerative colitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186548A Division JP2023010890A (ja) 2016-08-03 2022-11-22 潰瘍性大腸炎を治療するための方法

Publications (3)

Publication Number Publication Date
JP2019525944A JP2019525944A (ja) 2019-09-12
JP2019525944A5 JP2019525944A5 (enExample) 2020-09-17
JP7737219B2 true JP7737219B2 (ja) 2025-09-10

Family

ID=61071386

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019505410A Active JP7737219B2 (ja) 2016-08-03 2017-08-02 潰瘍性大腸炎を治療するための方法
JP2022186548A Pending JP2023010890A (ja) 2016-08-03 2022-11-22 潰瘍性大腸炎を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022186548A Pending JP2023010890A (ja) 2016-08-03 2022-11-22 潰瘍性大腸炎を治療するための方法

Country Status (7)

Country Link
US (5) US20180036352A1 (enExample)
EP (1) EP3493822A1 (enExample)
JP (2) JP7737219B2 (enExample)
CN (1) CN109803667A (enExample)
AU (1) AU2017306303B2 (enExample)
CA (1) CA3032004A1 (enExample)
WO (1) WO2018026913A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3045383B1 (fr) 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
CN116196425A (zh) 2016-09-27 2023-06-02 得克萨斯系统大学评议会 通过调节微生物组来增强免疫检查点阻断疗法的方法
EP3606325B1 (en) 2017-04-03 2024-09-04 Gusto Global, LLC Rational design of microbial-based biotherapeutics
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
KR102118203B1 (ko) * 2018-03-06 2020-06-02 주식회사 엠디헬스케어 코프로코커스 속 세균 유래 나노소포 및 이의 용도
FR3078627B1 (fr) * 2018-03-09 2020-11-13 Maat Pharma Procedure de collecte de selles et procede de preparation d'un echantillon pour transplantation de microbiote fecal
EP3597202A1 (en) * 2018-07-20 2020-01-22 Maat Pharma Fecal microbiota composition, for use in reducing treatment-induced inflammation
CA3114423A1 (en) * 2018-09-27 2020-04-02 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
CN109394795A (zh) * 2018-10-23 2019-03-01 上海市第十人民医院 一种肠菌胶囊制备方法及肠菌胶囊
CA3120709A1 (en) 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer
US20220080001A1 (en) * 2019-01-16 2022-03-17 Board Of Regents, The University Of Texas System Methods and compositions for treating immune checkpoint inhibitor associated colitis
CA3147629A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
US20230087012A1 (en) * 2020-02-14 2023-03-23 Cornell University Transferable microbiota for the treatment of ulcerative colitis
US20220120746A1 (en) * 2020-03-18 2022-04-21 Sabine Hazan Methods of Determining Susceptibility to COVID-19 Infection
US11744866B2 (en) * 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
US20230230697A1 (en) * 2020-06-29 2023-07-20 Icahn School Of Medicine At Mount Sinai Systems and methods for evaluating a subject for inflammatory bowel disease management
CN111888381A (zh) * 2020-09-18 2020-11-06 广西细微生物科技有限责任公司 一种肠道微生物移植工艺
AU2021405816A1 (en) * 2020-12-23 2023-07-06 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Method of expanding a complex community of microorganisms
CN113509494A (zh) * 2021-09-06 2021-10-19 南京医科大学 普氏菌在制备治疗胆汁淤积性疾病的药物中的应用
CN114246886B (zh) * 2021-12-24 2023-05-30 山西大学 规则粪球菌在制备预防和治疗急性结肠炎的制剂中的应用
CN115478031B (zh) * 2022-09-28 2025-04-18 中国科学院深圳先进技术研究院 防治炎症性肠病的胆汁酸代谢菌及其应用
KR20240114298A (ko) * 2023-01-12 2024-07-23 에스엔제이 파마 인크 감염 저항성 장내 균주 및 그 용도
CN119868571B (zh) * 2025-01-23 2025-11-21 浙江大学 扭链瘤胃球菌及其修饰菌在制备治疗溃疡性结肠炎的产品中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501095A (ja) 2000-05-11 2004-01-15 アンスティテュ　ナショナール　ド　ラ　ルシェルシュ　アグロノミク 消化器系障害の予防または治療のための水素依存性酢酸生成株の使用
JP2016521704A (ja) 2013-06-05 2016-07-25 レビオティクス インコーポレイテッドＲｅｂｉｏｔｉｘ，Ｉｎｃ． 微生物叢回復療法（ｍｒｔ）、組成物および製造方法

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828E (fr) 1901-08-19 1904-06-30 Louis Emile Albert Durand Machine agricole dénommée gratteuse-bineuse-sulfateuse, destinée à travailler et sulfater simultanément les vignes ou tous végétaux plantés en rang
FR1275E (fr) 1902-02-21 1903-07-01 Buil Francois Sebastien Joseph Système de fixation des poignées de vélocipèdes
FR2427E (fr) 1903-08-19 1904-04-07 Paul Steinmetz Carburateur doseur, pour moteurs à explosion
FR5528E (fr) 1905-03-16 1906-05-02 Farcot Freres Et Cie Soc Perfectionnements aux turbines à vapeur ou à gaz
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
FR1275M (fr) 1961-05-06 1962-05-02 Rene Roger Médicament a base de colibacilles vivants.
BE634858A (enExample) 1962-07-19 1900-01-01
FR2828M (fr) 1963-03-01 1964-11-02 Lucien Nouvel Médicament renfermant des colibacilles antibiorésistants.
FR5528M (enExample) 1965-10-01 1967-11-13
GB1271674A (en) 1968-07-09 1972-04-26 Nisshin Flour Milling Co Process and preparation for treating diarrhoea in pigs
SE371209B (enExample) 1969-10-13 1974-11-11 Cernelle Ab
DE2134179A1 (de) 1971-07-09 1973-01-25 Rolf Dr Schuler Bifidobakterien enthaltendes praeparat und verfahren zur herstellung desselben
FR2244464A1 (en) 1973-06-26 1975-04-18 Serozym Laboratoires Yeast, lacto- and colibacillus based compsns - used to modify intestinal flora, treat colitis and digestive disorders, etc.
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
US4335107A (en) 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4309782A (en) 1980-09-11 1982-01-12 Esteban Paulin Device for collecting fecal specimens
US4536409A (en) 1981-01-23 1985-08-20 American Can Company Oxygen scavenger
US4394377A (en) 1981-07-31 1983-07-19 Syntex (U.S.A.) Inc. Ruminant animal performance by co-administering choline and propionate enchancers
US4452779A (en) 1982-02-03 1984-06-05 Cockerill Vernon Composition and method of treating lactating mammals
FI840816A0 (fi) 1984-03-01 1984-03-01 Farmos Oy Bakteriepreparat
JPS615022A (ja) 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd 腸内細菌叢改善剤
US4892731A (en) 1986-12-11 1990-01-09 Tadashi Arai Biological intestinal antiseptics
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
US4948734A (en) 1987-08-12 1990-08-14 Mycogen Corporation Novel isolates of bacillus thuringiensis having activity against nematodes
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5266315A (en) 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
JP3047143B2 (ja) 1992-04-24 2000-05-29 堀井薬品工業株式会社 腸管洗浄液用組成物及び腸管洗浄液
JP3850891B2 (ja) 1994-03-01 2006-11-29 ゼリア新薬工業株式会社 緩下効果を有する組成物
JPH07242557A (ja) 1994-03-03 1995-09-19 Ss Pharmaceut Co Ltd 乳酸菌含有瀉下薬組成物
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
CN1094972C (zh) 1994-05-26 2002-11-27 伯拉考公司 人类来源的乳酸杆菌菌株、它们的组合物及其应用
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5800821A (en) 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5858356A (en) 1995-12-21 1999-01-12 Abbott Laboratories Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
AU1819897A (en) 1996-09-26 1998-04-17 Cuperman, Vladimir Borisovich Medicinal prophylactic "trisan"
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
US7374753B1 (en) 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US6428783B1 (en) 1998-03-11 2002-08-06 Medtech Center, Inc. Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men
US5902743A (en) 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
CN1300318A (zh) 1998-05-06 2001-06-20 中村启次郎 含有性质不同且彼此共生的微生物和其代谢物的微生物培养物,含有该培养物活性组分的载体和吸附剂及其用途
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
AT407008B (de) 1998-08-06 2000-11-27 Viernstein Helmut Dr Formulierungen mit probiotisch wirksamen mikroorganismen
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
AU6049599A (en) 1998-09-17 2000-04-03 Baxter Healthcare Sa Streptococcal c beta protein compositions
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US6479051B1 (en) 1998-12-11 2002-11-12 Urex Biotex, Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
WO2000051570A1 (fr) 1999-02-26 2000-09-08 Shionogi & Co., Ltd. Capsules molles a croquer presentant des proprietes d'administration ameliorees et leur procede de production
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US6756032B1 (en) 2000-07-12 2004-06-29 The Procter & Gamble Company Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
CA2416120A1 (en) 2000-07-17 2002-01-24 Svend Laulund Methods and formulations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7214370B2 (en) 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US6790453B2 (en) 2001-03-14 2004-09-14 Mccormick & Company, Inc. Encapsulation compositions and process for preparing the same
US7815956B2 (en) 2001-04-27 2010-10-19 Pepsico Use of erythritol and D-tagatose in diet or reduced-calorie beverages and food products
EP1411900B2 (en) 2001-06-01 2013-12-04 Pozen, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
JPWO2003004003A1 (ja) 2001-07-05 2004-10-21 湧永製薬株式会社 ソフトカプセル剤
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
CA2478515C (en) 2002-04-05 2010-09-28 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
CA2391422A1 (en) 2002-07-12 2004-01-12 David William Molloy Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,...
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
KR20060073937A (ko) 2003-08-18 2006-06-29 더 바이오 밸런스 코포레이션 안정한 액상 촉생제 조성물, 그의 제조 및 응용
US7759105B2 (en) 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20060177424A1 (en) 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8016816B2 (en) 2003-09-09 2011-09-13 Convatec Technologies Inc. Fecal management appliance and method and apparatus for introducing same
US7541091B2 (en) 2004-05-18 2009-06-02 M & G Usa Corporation Compartmentalized resin pellets for oxygen scavenging
BRPI0418986A (pt) 2004-08-05 2007-12-11 Anidral Srl cepas bacterianas bifidobacterium produtoras de ácido fólico, formulações e seus usos
EP1800688A1 (en) 2004-08-05 2007-06-27 Anidral S.R.L. Folic acid producing bifidobacterium bacterial strains, formulations and use thereof
US20060076536A1 (en) 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
CN101217945B (zh) 2005-05-20 2012-07-11 陶氏环球技术有限责任公司 使用射频识别标签的口服用药依从性监视
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
TWI362949B (en) 2005-09-13 2012-05-01 Bion Tech Inc Intestines dissolving nature is able to bear the hydrochloric acid in gastric juice and wrap up the benefit covered and grow the fungus of makes up
EP1970055B1 (en) 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
JP5006567B2 (ja) 2006-04-14 2012-08-22 花王株式会社 口腔用固形製剤
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
JP2008106066A (ja) 2006-09-25 2008-05-08 Tashiro Yasuaki サポニン及び生菌を含有する組成物
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
HRP20140080T1 (hr) 2007-03-01 2014-03-14 Probi Ab Uporaba lactobacillus plantarum za poveä†anje bakterijske raznolikosti
RU2473681C2 (ru) 2007-03-28 2013-01-27 Элиментари Хелт Лимитед ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ТАКОЙ ШТАММ, И ЕГО ПРИМЕНЕНИЕ
RU2466185C2 (ru) 2007-03-28 2012-11-10 Элиментари Хелт Лимитед ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, ПРОБИОТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЯ ШТАММА Bifidobacterium longum
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
WO2008148734A1 (de) 2007-06-06 2008-12-11 Basf Se Pharmazeutische formulierung für die herstellung von kau- und lutsch-tabletten
KR101903781B1 (ko) 2007-06-06 2018-11-13 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
BRPI0814175A2 (pt) 2007-07-27 2015-01-20 Cargill Inc Micronização de polióis
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
ATE548423T1 (de) 2007-08-31 2012-03-15 Invista Tech Sarl Sauerstoffabsorbierende kunststoffzusammensetzungen
JP5537943B2 (ja) 2007-09-27 2014-07-02 田辺三菱製薬株式会社 速崩壊性固形製剤
PT2572705T (pt) 2007-10-01 2017-11-08 Lesvi Laboratorios Sl Comprimidos orodispersíveis
WO2009052391A1 (en) 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
ES2431572T3 (es) 2007-10-20 2013-11-27 Université de Liège Especies bifidobacterianas
CA2740434C (en) 2007-10-26 2017-11-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
JP5258268B2 (ja) 2007-11-19 2013-08-07 フロイント産業株式会社 球形粒の製造方法
EP2233129B1 (en) 2007-12-28 2014-05-07 Sawai Pharmaceutical Co., Ltd. Oral cavity disintegrating tablet and method of producing the same
SMT202400116T1 (it) 2008-10-02 2024-05-14 Salix Pharmaceuticals Ltd Trattamento dell’encefalopatia epatica utilizzando rifaximina
US20100178413A1 (en) 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
US20100255231A1 (en) 2009-04-01 2010-10-07 Multisorb Technologies, Inc. Oxygen scavenging films
KR101821417B1 (ko) 2009-04-30 2018-01-23 인트랙슨 액토바이오틱스 엔.브이. 유산균의 냉동건조에 사용하기 위한 냉동보호제
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
WO2010138439A1 (en) 2009-05-28 2010-12-02 Aptapharma, Inc. Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations
CN201441672U (zh) 2009-07-14 2010-04-28 赵伟华 一次性灌肠装置
US20110045222A1 (en) 2009-08-19 2011-02-24 Eastman Chemical Company Oxygen-scavenging polymer blends suitable for use in packaging
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
WO2011046616A2 (en) 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
US20110218216A1 (en) 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
WO2011094027A1 (en) 2010-02-01 2011-08-04 Hlavka Edwin J Bacteriotherapy for clostridium difficile colitis
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
US8853269B2 (en) 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
AU2011226324B2 (en) 2010-03-10 2015-09-24 Nogra Pharma Limited Compositions for colon lavage and methods of making and using same
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
KR102435108B1 (ko) 2010-08-04 2022-08-22 핀치 테라퓨틱스 홀딩스 엘엘씨 분변 세균총 이식을 위한 조성물, 그의 제조 방법과 사용 방법, 및 그를 전달하기 위한 장치
WO2012045150A1 (en) 2010-10-04 2012-04-12 British Columbia Cancer Agency Branch Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
HUE038600T2 (hu) 2010-10-07 2018-10-29 California Inst Of Techn Probiotikus terápiák autizmushoz
WO2014152484A1 (en) * 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
CN103561752B (zh) 2011-03-09 2016-04-20 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
US20150374761A1 (en) 2011-03-09 2015-12-31 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
US20140363397A1 (en) 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
EA201490512A1 (ru) 2011-10-11 2014-09-30 Ачим Байотерапьютикс Аб Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
EP2785828B1 (en) 2011-12-01 2020-04-08 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
US9176026B2 (en) 2011-12-15 2015-11-03 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
US8993259B2 (en) 2012-05-02 2015-03-31 Charles River Laboratories, Inc. Method of viability staining with membrane permeable fluorescent dye and membrane impermeable fluorescence quencher
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2890808A4 (en) 2012-08-29 2016-09-28 California Inst Of Techn DIAGNOSIS AND TREATMENT OF AUTISTICAL DISEASES
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
JP2016501852A (ja) * 2012-11-26 2016-01-21 トーマス・ジュリアス・ボロディ 糞便微生物叢の回復のための組成物、ならびにそれらを作製および使用する方法
US11185562B2 (en) 2013-02-04 2021-11-30 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN105307654B (zh) 2013-04-30 2022-06-07 托马斯·朱利叶斯·波洛迪 用于治疗微生物区系相关的精神病况和疾病的组合物和方法
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
JP2016530239A (ja) 2013-07-09 2016-09-29 ピュアテック ベンチャーズ、エルエルシー 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物
AU2014331610B2 (en) 2013-10-03 2019-11-07 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CA2985827A1 (en) 2015-05-14 2016-11-17 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
NZ776366A (en) 2015-05-22 2023-02-24 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
WO2017075098A1 (en) 2015-10-26 2017-05-04 Crestovo Llc Compositions and methods for fecal microbiota-related therapy
EP4249053A3 (en) 2016-03-04 2024-06-19 The Regents of The University of California Microbial consortium and uses thereof
US20180036352A1 (en) * 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501095A (ja) 2000-05-11 2004-01-15 アンスティテュ　ナショナール　ド　ラ　ルシェルシュ　アグロノミク 消化器系障害の予防または治療のための水素依存性酢酸生成株の使用
JP2016521704A (ja) 2013-06-05 2016-07-25 レビオティクス インコーポレイテッドＲｅｂｉｏｔｉｘ，Ｉｎｃ． 微生物叢回復療法（ｍｒｔ）、組成物および製造方法

Also Published As

Publication number Publication date
US12390496B2 (en) 2025-08-19
US20200113949A1 (en) 2020-04-16
US20180036352A1 (en) 2018-02-08
CN109803667A (zh) 2019-05-24
JP2023010890A (ja) 2023-01-20
AU2017306303B2 (en) 2025-01-02
AU2017306303A1 (en) 2019-02-14
US20180125899A1 (en) 2018-05-10
WO2018026913A1 (en) 2018-02-08
US10195235B2 (en) 2019-02-05
CA3032004A1 (en) 2018-02-08
US10561690B2 (en) 2020-02-18
US20190175665A1 (en) 2019-06-13
US11071759B2 (en) 2021-07-27
EP3493822A1 (en) 2019-06-12
JP2019525944A (ja) 2019-09-12
US20210330717A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US12390496B2 (en) Methods for treating ulcerative colitis
JP7273082B2 (ja) 自閉症スペクトラム障害および関連する症候を治療するための方法
US20210106629A1 (en) Compositions and Methods for Treating Inflammatory Bowel Diseases (IBDs) and Other Disorders
JP2018535254A (ja) 便微生物叢関連療法のための組成物及び方法
US20210121503A1 (en) Fecal microbiota transplantation for treating ulcerative colitis
US11213549B2 (en) Compositions and method for treating primary sclerosing cholangitis and related disorders
US20210275603A1 (en) Compositions and Methods for Treating Irritable Bowel Syndrome and Related Disorders
US20240173360A1 (en) Compositions and methods for treating epilepsy and related disorders
US20180099011A1 (en) Compositions and Methods for Treating Irritable Bowel Syndrome and Related Disorders
US20200188449A1 (en) Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders
WO2021097288A1 (en) Compositions and methods for treating neurodegenerative diseases
US20200197449A1 (en) Compositions and Methods for Treating Alopecia and Related Disorders
US20180099013A1 (en) Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders
HK40009325A (zh) 用於治疗溃疡性结肠炎的方法
WO2021142347A1 (en) Compositions and methods for non-alcoholic steatohepatitis (nash)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230516

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230619

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250829

R150 Certificate of patent or registration of utility model

Ref document number: 7737219

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150